{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:50:52Z","timestamp":1788378652129,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early diagnosis and accurate monitoring of disease progression are crucial for timely therapeutic intervention in hereditary transthyretin amyloidosis (ATTRv). Neurofilament light chain (NfL) has emerged as a sensitive biomarker of neuroaxonal injury across neurodegenerative disorders. This study aimed to investigate serum levels of NfL, glial fibrillary acidic protein (GFAP), and peripherin (PRPH) in patients with ATTRV30M amyloidosis and pre-symptomatic gene carriers, compared with controls. Serum samples from 34 ATTRV30M patients, 17 pre-symptomatic ATTRV30M carriers, and 35 controls were analysed using conventional commercially available ELISA platforms to quantify NfL, GFAP, and PRPH concentrations. Serum NfL (sNfL) levels were significantly elevated in ATTRV30M patients compared with controls (threefold,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0005) and were 1.6-fold higher than in pre-symptomatic ATTRV30M carriers. No significant differences were observed between pre-symptomatic carriers and controls. sNfL concentrations were higher in patients with polyneuropathy disability (PND) score\u2009&gt;\u2009I compared with PND I (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0007). Serum GFAP and PRPH levels did not differ significantly among the study groups. Serum NfL represents a promising non-invasive biomarker for assessment of early symptomatic disease and monitoring of disease progression in ATTRV30M amyloidosis. In contrast, sGFAP and sPRPH appear to have limited diagnostic utility in this context.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-56777-y","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:23:22Z","timestamp":1780939402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of serum neurofilament light chain, GFAP, and peripherin as biomarkers in hereditary transthyretin amyloidosis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-7643","authenticated-orcid":false,"given":"Intissar","family":"Anan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-3971","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Pilebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-1277","authenticated-orcid":false,"given":"Jonas","family":"Wixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3391-3271","authenticated-orcid":false,"given":"Victoria","family":"Heldestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1972-4071","authenticated-orcid":false,"given":"Sandra","family":"Arvidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-6487","authenticated-orcid":false,"given":"Malin","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"3","key":"56777_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1258\/acb.2011.011225","volume":"49","author":"JH Pinney","year":"2012","unstructured":"Pinney, J. H., Hawkins, P. N. & Amyloidosis Ann. Clin. Biochem. 49 (3), 229\u2013241. (2012).","journal-title":"Ann. Clin. Biochem."},{"issue":"4","key":"56777_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","volume":"54","author":"RA Kyle","year":"1975","unstructured":"Kyle, R. A. & Bayrd, E. D. Amyloidosis: review of 236 cases. Med. (Baltim). 54 (4), 271\u2013299 (1975).","journal-title":"Med. (Baltim)."},{"issue":"12","key":"56777_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plante-Bordeneuve","year":"2011","unstructured":"Plante-Bordeneuve, V. & Said, G. Familial amyloid polyneuropathy. Lancet Neurol. 10 (12), 1086\u20131097 (2011).","journal-title":"Lancet Neurol."},{"issue":"Suppl 1","key":"56777_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","volume":"29","author":"Y Parman","year":"2016","unstructured":"Parman, Y. et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? Curr. Opin. Neurol. 29 (Suppl 1), S3\u2013S13 (2016).","journal-title":"Curr. Opin. Neurol."},{"issue":"29","key":"56777_CR5","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1074\/jbc.M101024200","volume":"276","author":"A Quintas","year":"2001","unstructured":"Quintas, A. et al. Tetramer dissociation and monomer partial unfolding precede protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276 (29), 27207\u201327213 (2001).","journal-title":"J. Biol. Chem."},{"issue":"50","key":"56777_CR6","doi-asserted-by":"publisher","first-page":"16612","DOI":"10.1021\/bi0511484","volume":"44","author":"RL Wiseman","year":"2005","unstructured":"Wiseman, R. L., Powers, E. T. & Kelly, J. W. Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry 44 (50), 16612\u201316623 (2005).","journal-title":"Biochemistry"},{"issue":"2","key":"56777_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/path.1759","volume":"206","author":"J Bergstr\u00f6m","year":"2005","unstructured":"Bergstr\u00f6m, J. et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J. Pathol. 206 (2), 224\u2013232 (2005).","journal-title":"J. Pathol."},{"issue":"4","key":"56777_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr, O. B., Lundgren, E. & Westermark, P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J. Intern. Med. 281 (4), 337\u2013347 (2017).","journal-title":"J. Intern. Med."},{"issue":"1","key":"56777_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho, T., Maurer, M. S. & Suhr, O. B. The Transthyretin Amyloidosis Outcomes Survey (THAOS): initial report on clinical manifestations in hereditary and wild-type transthyretin amyloidosis. Curr. Med. Res. Opin. 29 (1), 63\u201376 (2013).","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"56777_CR10","doi-asserted-by":"publisher","first-page":"e0143456","DOI":"10.1371\/journal.pone.0143456","volume":"10","author":"S Arvidsson","year":"2015","unstructured":"Arvidsson, S. et al. Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis: impact of sex and amyloid fibril composition. PLoS One. 10 (11), e0143456 (2015).","journal-title":"PLoS One"},{"issue":"5","key":"56777_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/s-0039-1688994","volume":"39","author":"M Kaku","year":"2019","unstructured":"Kaku, M. & Berk, J. L. Neuropathy associated with systemic amyloidosis. Semin Neurol. 39 (5), 578\u2013588 (2019).","journal-title":"Semin Neurol."},{"issue":"2","key":"56777_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-0404.1981.tb00753.x","volume":"63","author":"S Blom","year":"1981","unstructured":"Blom, S., Steen, L. & Zetterlund, B. Familial amyloidosis with polyneuropathy type 1: a neurophysiological study of peripheral nerve function. Acta Neurol. Scand. 63 (2), 99\u2013110 (1981).","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"56777_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/mus.20689","volume":"35","author":"V Heldestad","year":"2007","unstructured":"Heldestad, V. & Nordh, E. Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy. Muscle Nerve. 35 (2), 189\u2013195 (2007).","journal-title":"Muscle Nerve"},{"issue":"3","key":"56777_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00125-022-05846-8","volume":"66","author":"H Maalmi","year":"2023","unstructured":"Maalmi, H. et al. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia 66 (3), 579\u2013589 (2023).","journal-title":"Diabetologia"},{"issue":"1","key":"56777_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","volume":"28","author":"J Louwsma","year":"2021","unstructured":"Louwsma, J. et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid 28 (1), 50\u201355 (2021).","journal-title":"Amyloid"},{"issue":"10","key":"56777_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14 (10), 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"56777_CR17","doi-asserted-by":"publisher","first-page":"689938","DOI":"10.3389\/fnins.2021.689938","volume":"15","author":"A Yuan","year":"2021","unstructured":"Yuan, A. & Nixon, R. A. Neurofilament proteins as biomarkers to monitor neurological diseases and therapeutic efficacy. Front. Neurosci. 15, 689938 (2021).","journal-title":"Front. Neurosci."},{"issue":"3","key":"56777_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.acthis.2006.03.011","volume":"108","author":"P Westermark","year":"2006","unstructured":"Westermark, P. et al. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem. 108 (3), 209\u2013213 (2006).","journal-title":"Acta Histochem."},{"issue":"2","key":"56777_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","volume":"27","author":"LF Maia","year":"2020","unstructured":"Maia, L. F. et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27 (2), 97\u2013102 (2020).","journal-title":"Amyloid"},{"issue":"38","key":"56777_CR20","doi-asserted-by":"publisher","first-page":"e22363","DOI":"10.1097\/MD.0000000000022363","volume":"99","author":"W Gao","year":"2020","unstructured":"Gao, W. et al. Neurofilament light chain level in traumatic brain injury: a systematic review and meta-analysis. Med. (Baltim). 99 (38), e22363 (2020).","journal-title":"Med. (Baltim)."},{"key":"56777_CR21","doi-asserted-by":"publisher","first-page":"921809","DOI":"10.3389\/fnagi.2022.921809","volume":"14","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Neurofilament light chain: a candidate biomarker of perioperative stroke. Front. Aging Neurosci. 14, 921809 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"56777_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fnins.2020.00579","volume":"14","author":"T Loeffler","year":"2020","unstructured":"Loeffler, T. et al. Neurofilament-light chain as a biomarker of neurodegenerative and rare diseases with high translational value. Front. Neurosci. 14, 579 (2020).","journal-title":"Front. Neurosci."},{"key":"56777_CR23","first-page":"108490","volume":"104","author":"L Heimfarth","year":"2022","unstructured":"Heimfarth, L. et al. Serum glial fibrillary acidic protein as a body-fluid biomarker of neurological disorders: a systematic review. Int. Immunopharmacol. 104, 108490 (2022).","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"56777_CR24","first-page":"e239943","volume":"6","author":"AL K\u00fchn","year":"2023","unstructured":"K\u00fchn, A. L. & Petzold, A. Types and concentrations of blood-based biomarkers in adults with peripheral neuropathy: a systematic review and meta-analysis. JAMA Netw. Open. 6 (3), e239943 (2023).","journal-title":"JAMA Netw. Open."},{"issue":"5","key":"56777_CR25","doi-asserted-by":"publisher","first-page":"13072","DOI":"10.1007\/s00415-025-13072-6","volume":"272","author":"D Plantone","year":"2025","unstructured":"Plantone, D. et al. Elevated serum concentrations of glial fibrillary acidic protein in hereditary transthyretin amyloidosis since pre-symptomatic stages. J. Neurol. 272 (5), 13072\u201313076 (2025).","journal-title":"J. Neurol."},{"issue":"2","key":"56777_CR26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/brain\/awac092","volume":"146","author":"S Keddie","year":"2023","unstructured":"Keddie, S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 146 (2), 645\u2013659 (2023).","journal-title":"Brain"},{"key":"56777_CR27","doi-asserted-by":"publisher","unstructured":"Plantone, D. et al. Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study. Amyloid 16, 1\u201310. https:\/\/doi.org\/10.1080\/13506129.2026.2640984 (2026).","DOI":"10.1080\/13506129.2026.2640984"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56777-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:39:20Z","timestamp":1780940360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56777-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56777"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56777-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All participants provided written informed consent prior to inclusion. The study was approved by the Swedish Ethical Review Authority (reference number 2021-06145-02) and performed in accordance with the Helsinki declaration. The data protection guidelines (GDPR) were applied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"17697"}}